Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02915705 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
A Phase 3 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT02915705 is a Phase 3 study that has completed, run by Kyowa Kirin. The registered enrollment target is 61 participants.
The verdict
NCT02915705, a Phase 3 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).
Interventions
- BIOLOGICAL burosumab
- DRUG Oral Phosphate Supplement
- DRUG active vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-09-08 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02915705
The ClinicalTrials.gov registry entry for NCT02915705 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which burosumab is the first listed.
NCT02915705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02915705 about?
NCT02915705 is a clinical study titled "Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH". The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).
What is the current status of trial NCT02915705?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2016-09-08. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT02915705?
The interventions under investigation include: burosumab (BIOLOGICAL), Oral Phosphate Supplement (DRUG), active vitamin D (DRUG).
Who is sponsoring clinical trial NCT02915705?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.